©2022 Stanford Medicine
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Not Recruiting
Trial ID: NCT00185848
Purpose
The purpose of this study is to determine whether [18F]FHBG is suitable for use as an imaging
probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In
this phase 1 study we will assess the safety and biodistribution of [18F]FHBG in patients.
Official Title
Imaging the Biodistribution of the Positron Emission Tomography Reporter Probe, [18F]FHBG, in Humans.
Stanford Investigator(s)
Eligibility
Inclusion Criteria:
- Clinical diagnosis of brain tumor or rheumatoid arthritis
Exclusion Criteria:
- Below 18 years of age
Intervention(s):
radiation: [18F]FHBG
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
ccto-office@stanford.edu
650-498-7061